Elucid, a Boston-based medical technology company developing AI-powered cardiovascular diagnostics software, has appointed Mark Miller as chief revenue officer. Miller will lead the company's commercial expansion ahead of the anticipated FDA clearance of its BioIntegrated FFR-CT software. Miller brings over 25 years of experience in cardiovascular imaging and diagnostics sales. He previously spent a decade at GE Healthcare and Philips, and served as vice president of sales at Cassling, where he led a commercial team of more than 40 professionals. Elucid's platform includes its FDA-cleared Plaque-IQ software and the pending BioIntegrated FFR-CT solution, which helps physicians identify coronary blockages non-invasively. The company focuses on advancing precision diagnosis of cardiovascular disease through AI-enabled image analysis.

Elucid, a Boston-based medical technology company, has raised $55 million in an oversubscribed Series D financing round, bringing its total funding to approximately $185 million. The round includes participation from a large medtech company, joining as Elucid's fourth publicly traded strategic investor, alongside IAG Capital Partners and Elevage Medical Technologies. The funding will accelerate commercialisation of Elucid's AI-powered cardiovascular imaging platform. The company is preparing for full commercial launch of its BioIntegrated FFR-CT product, currently under FDA review, alongside its FDA-cleared Plaque-IQ software. Elucid's technology converts routine CT angiography into detailed insights based on plaque biology, vessel anatomy, and physiology, helping clinicians stratify at-risk patients and personalise treatment strategies for atherosclerotic cardiovascular disease.